GlassScriptPhysician profile
Ciera Lashon Semere
NPI 1376217018
$1,018.98
in general payments reported to CMS, 2019-2025
15 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $162 · 2023: $356 · 2024: $313 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $400.28 | 2022-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $97.46 | 2022-2023 | |
| Boston Scientific Corporation | $96.84 | 2023 | Resonate El Icd Vr |
| Pfizer INC. | $92.50 | 2022-2025 | |
| Amgen INC. | $66.44 | 2023-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $43.42 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $38.00 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $34.64 | 2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $29.22 | 2023-2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $28.07 | 2024 | Onpattro |
| Abbott Laboratories | $24.96 | 2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $19.77 | 2025 | Wainua |
| Phadia US INC. | $16.84 | 2022 | |
| Siemens Medical Solutions USA, INC. | $16.38 | 2022 | |
| Esperion Therapeutics, INC. | $14.16 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ciera Semere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.